Journal article Open Access

Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH randomised, controlled trial

Charalampia Amerikanou; Stavroula Kanoni; Andriana C. Kaliora; Angela Barone; Mladen Bjelan; Giuseppe D'Auria; Aristea Gioxari; María José Gosalbes; Sofia Mouchti; Maria G. Stathopoulou; Beatriz Soriano; Stefan Stojanoski; Rajarshi Banerjee; Maria Halabalaki; Eleni V. Mikropoulou; Aimo Kannt; John Lamont; Carlos Llorens; Fernando Marascio; Miriam Marascio; Francisco J. Roig; Ilias Smyrnioudis; Iraklis Varlamis; Sophie Visvikis-Siest; Milan Vukic; Natasa Milic; Milica Medic-Stojanoska; Lucia Cesarini; Jonica Campolo; Amalia Gastaldelli; Panos Deloukas; Maria Giovanna Trivella; M. Pilar Francino; George V. Dedoussis

NAFLD is an emerging public health issue globally and its prevalence is consistently increasing. Since there is no approved therapy for this liver disease and given that pharmacological treatment will be approved only for NASH, we wanted to investigate if Mastiha could be a non-pharmacological modulator of NAFLD markers.

Mastiha, has been shown to possess antioxidant/anti- inflammatory and lipid lowering properties and could have beneficial effects on hepatic and systemic parameters in subjects with NAFLD. To this aim we designed, MAST4HEALTH, a Marie Sklodowska-Curie Actions (MSCA) Research and Innovation Staff Exchange (RISE) program under the EU Horizon 2020 framework. MAST4HEALTH is a multicenter randomized double blind placebo controlled clinical trial to test Mastiha’s effectiveness as new non-pharmacologic strategy for NAFLD treatment (NCT03135873).

After 6-months of Mastiha supplementation, we observed a significant improvement on microbiota dysbiosis and lipid metabolite levels in patients with NAFLD. Among  severely obese patients, Mastiha also reduced markers of liver fibrosis (as assessed via MRI).

This is the pre-peer reviewed version which has been published in final form at 10.1002/mnfr.202001178. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

Files (13.9 MB)
Name Size
Figure1.tif
md5:48ddc9a9387911997e641b19f89e64fb
9.7 MB Download
Figure2.tif
md5:c67a4517b15c404f66b113f98879573f
924.3 kB Download
Figure3.tif
md5:edb9802039b47383192a5ffe5a0889ae
924.3 kB Download
Manuscript.docx
md5:77bea2b066d1aad69a698d7be95be5e7
90.6 kB Download
Supporting information tables.xlsx
md5:da2d9d717048e5aebe553789f6551a30
30.0 kB Download
Supporting information.docx
md5:c0008abad9672759161d45430961d8ed
2.2 MB Download
63
23
views
downloads
Views 63
Downloads 23
Data volume 69.0 MB
Unique views 57
Unique downloads 11

Share

Cite as